Ischemic stroke as a consequence of coagulopathy in coronavirus disease


  • H.S. Trepet Bogomolets National Medical University, Kyiv, Ukraine
  • L.M. Trepet MNPE “Oleksandrivska Clinical Hospital”, Kyiv, Ukraine
  • Ya.A. Havryliuk Bogomolets National Medical University, Kyiv, Ukraine



ischemic stroke, coronavirus disease, D-dimer, neurologic deficit, C-reactive protein


Objective: to compare the state of the coagulation system in patients with ischemic stroke and coronavirus disease in those with ischemic stroke without coronavirus disease. Materials and methods. We examined 40 patients in the acute period of cerebral ischemic stroke, aged from 69 to 87 years (average age of 77.30 ± 2.08 years). They were divided into two groups: group I — SARS-CoV-2-positive, group II — SARS-CoV-2-negative. Group I consisted of 20 individuals (9 women and 11 men) aged 69 to 84 years (average age of 76.9 ± 3.0 years). Group II included 20 patients (10 women and 10 men) aged 72 to 87 years (average age of 78.5 ± 2.5 years). Results. Twelve (60 %) patients of group I had a moderate disease severity, 8 (40 %) — severe. The severity of neurologic deficits on the National Institutes of Health Stroke Scale did not differ significantly in patients of both clinical groups: in group I it was 14.0 ± 0.7 points, in group II — 10.00 ± ± 1.37 points, which corresponded to moderate stroke, the significance level p = 0.05. In the neurological status, motor and sensory deficits were observed in both groups in combination with speech disorders and ataxia. The average level of prothrombin index in group I was 101 ± 6 %, in II — 83 ± 2 %, p = 0.01. The level of fibrinogen in group I was 401.0 ± 18.6 mg/dl, in group II — 250 ±
± 12 mg/dl, which can lead to temporary hypercoagulation and the development of thromboembolism (p < 0.05). In group I, the level of D-dimer was 465 ± 8 ng/ml, in group II — 175 ± 4 ng/ml
(p < 0.05). Conclusions. The data suggest that SARS-CoV-2-posi-tive patients with ischemic stroke compared to SARS-CoV-2-ne-gative ones with ischemic stroke are characterized by the presence of coagulopathy, as evidenced by significantly higher levels of fibrinogen, prothrombin index, D-dimer and moderate thrombocytopenia, as well as significantly higher levels of C-reactive protein that indicates the presence of an acute inflammatory process, which also causes thrombosis.


Download data is not yet available.


Zhu N., Zhang D., Wang W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020. 382. 727-733.

Coronavirus: COVID-19. 18 November 2020.

Wang J., Hajizadeh N., Moore E.Е. et al. Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series. J. Thromb. Haemost. 2020. doi: 10.1111/jth.1482.

Iba T., Levy J.H., Levi M. et al. Coagulopathy of coronavirus disease 2019. Crit. Care Med. 2020. doi: 10.1097/CCM.0000000000004458.

Zhao Y., Zhao Z., Wang Y. et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. 2020. DOI: 10.1101/2020.01.26.919985.

Goshua G. et al. Endotheliopathy is essential in COVID-19 associated coagulopathy. EHA Congress. Abstract LB2605.

Machado С., Gutierrez J. Anosmia and Ageusia as Initial or Unique Symptoms after SARS-CoV-2 Virus. Preprints. Posted: 16 April 2020. DOI: 10.20944/preprints202004.0272.v1.

Keyhan S., Fallahi R., Cheshmi B. Dysosmia and dysgeusia due the novel 2019 novel Coronavirus: a hypothesis that needs further investigation. Maxyllofacial Plastic and Resonsctructive Surgery. 2020. 42.

Poyiadji N., Shahin G., Noujaim D., Stone M., Patel S., Griffith В. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. Published online: Mar 31, 2020.

Li Y., Wang M., Zhou Y. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. March 13, 2020.

Umapathi T., Kor A.С., Venketasubramanian N. et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J. Neurol. 2004. 251. 1227-1231.

Glatter R. Why Is COVID-19 Coronavirus Causing Strokes In Young And Middle-Aged People. Apr 27, 2020.

Rahma Beyrouti et al. Characteristics of ischaemic stroke associated with COVID-19. Journal of Neurology, Neurosurgery, and Psychiatry. 2020. DOI: 10.1136/jnnp-2020-323586.

Young K. COVID-19: Stroke in Young Adults/New Presentation in Kids/ACS Advissions. The New England Yournal of Medicine. 2020, April 28.

Ning Tang et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Klok F.A., Kruip M., van der Meer N.J.М. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb. Res. 2020. 191. 148-150.

Pinna P., Grewal P., Hall J.Р. et al. Neurological manifestations and COVID-19: experiences from a tertiary care center at the Frontline. J. Neurol. Sci. 2020. 415. 116969.

Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020. 77. 1-9.

Ömer Karadaş, Bilgin Öztürk, Ali Rıza Sonkaya. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurol. Sci. 2020. 41. 1991-1995.

Fan S., Xiao M., Han F. et al. Neurological manifestations in critically ill patients with COVID-19: a retrospective study. Front. Neurol. 2020. 11. 806. 21. Markus H.S. and Brainin M. COVID-19 and stroke — a global World Stroke Organization perspective. Int. J. Stroke. 2020. 15. 361-364.

Beyrouti R., Adams M.Е., Benjamin L. et al. Characteristics of ischemic stroke associated with COVID-19. J. Neurol. Neurosurg. Psychiatry. 2020. 91. 889-891.

Thachil J., Tang N., Gando S. еt al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb. Haemost. 2020 May. 18(5). 1023-1026. doi: 10.1111/jth.14810.

Садов’як І.Д., Микичак І.В. Протокол «Надання медичної допомоги для лікування коронавірусної хвороби (COVID-19)», Наказ МОЗ України № 2116, від 17 вересня 2020 року. 6-22.

Wada H., Thachil J., Di Nisio M. et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. J. Thromb. Haemost. doi: 10.1111/jth.12155.

Lahiri D., Ardila A. COVID-19 Pandemic: A Neurological Perspective. Cureus. 2020. 12(4). e7889. doi: 10.7759/cureus.7889.

Watanabe K. et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J. Clin. Biochem. Nutr. 2018 Jan. 62 (1). 20-38.

Pradhan B., Pradhan G., Pradhan D. Edaravone: A Free Radical Scavenger with Multiple Pleotropic Actions can be a Potential Game Changer Agent in Prevention and Alleviation of COVID-19 — Induced Cytokine Storm. Journal оf Medical Science And Clinical Research. 2020. 8 (7). 227-236.

Toth A.E., Walter F.R., Bocsik A. et al. Edaravone Protects against Methylglyoxal-Induced Barrier Damage in Human Brain Endothelial Cells. PLoS ONE. 2014. 9(7). e100152.



How to Cite

Trepet, H., Trepet, L., & Havryliuk, Y. (2021). Ischemic stroke as a consequence of coagulopathy in coronavirus disease. INTERNATIONAL NEUROLOGICAL JOURNAL, 17(2), 25–30.



Original Researches

Most read articles by the same author(s)